Lilly attracts Boehringer Ingelheim to diabetes venture
This article was originally published in Scrip
Executive Summary
Lilly and Boehringer Ingelheim have linked up on a broad venture to co-develop and co-commercialise four diabetes drugs in mid- and late-stage development, with opt-in rights for a fifth molecule, as Lilly in particular seeks to rejuvenate its diabetes business following a setback with its own pipeline late last year. Indeed, diabetes accounts for about 17% of Lilly sales – all its products are currently injectables - but in recent years the company has been losing ground in the marketplace to competitors such as NovoNordisk.